BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 30334671)

  • 21. Interference with PSMB4 Expression Exerts an Anti-Tumor Effect by Decreasing the Invasion and Proliferation of Human Glioblastoma Cells.
    Cheng YC; Tsai WC; Sung YC; Chang HH; Chen Y
    Cell Physiol Biochem; 2018; 45(2):819-831. PubMed ID: 29414809
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A polymeric temozolomide nanocomposite against orthotopic glioblastoma xenograft: tumor-specific homing directed by nestin.
    Prabhu S; Goda JS; Mutalik S; Mohanty BS; Chaudhari P; Rai S; Udupa N; Rao BSS
    Nanoscale; 2017 Aug; 9(30):10919-10932. PubMed ID: 28731079
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Small molecules targeting histone demethylase genes (KDMs) inhibit growth of temozolomide-resistant glioblastoma cells.
    Banelli B; Daga A; Forlani A; Allemanni G; Marubbi D; Pistillo MP; Profumo A; Romani M
    Oncotarget; 2017 May; 8(21):34896-34910. PubMed ID: 28432280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.
    Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S
    Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pyr3 Induces Apoptosis and Inhibits Migration in Human Glioblastoma Cells.
    Chang HH; Cheng YC; Tsai WC; Tsao MJ; Chen Y
    Cell Physiol Biochem; 2018; 48(4):1694-1702. PubMed ID: 30078005
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficient delivery of Temozolomide using ultrasmall large-pore silica nanoparticles for glioblastoma.
    Janjua TI; Cao Y; Ahmed-Cox A; Raza A; Moniruzzaman M; Akhter DT; Fletcher NL; Kavallaris M; Thurecht KJ; Popat A
    J Control Release; 2023 May; 357():161-174. PubMed ID: 36965857
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Amphetamine decorated cationic lipid nanoparticles cross the blood-brain barrier: therapeutic promise for combating glioblastoma.
    Saha S; Yakati V; Shankar G; Jaggarapu MMCS; Moku G; Madhusudana K; Banerjee R; Ramkrishna S; Srinivas R; Chaudhuri A
    J Mater Chem B; 2020 May; 8(19):4318-4330. PubMed ID: 32330214
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined inhibition of vascular endothelial growth factor receptor signaling with temozolomide enhances cytotoxicity against human glioblastoma cells via downregulation of Neuropilin-1.
    Lee J; Kim E; Ryu SW; Choi C; Choi K
    J Neurooncol; 2016 May; 128(1):29-34. PubMed ID: 26951556
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lactoferrin nanoparticle mediated targeted delivery of 5-fluorouracil for enhanced therapeutic efficacy.
    Kumari S; Kondapi AK
    Int J Biol Macromol; 2017 Feb; 95():232-237. PubMed ID: 27864056
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
    Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metronomic treatment in immunocompetent preclinical GL261 glioblastoma: effects of cyclophosphamide and temozolomide.
    Ferrer-Font L; Arias-Ramos N; Lope-Piedrafita S; Julià-Sapé M; Pumarola M; Arús C; Candiota AP
    NMR Biomed; 2017 Sep; 30(9):. PubMed ID: 28570014
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined anti-Galectin-1 and anti-EGFR siRNA-loaded chitosan-lipid nanocapsules decrease temozolomide resistance in glioblastoma: in vivo evaluation.
    Danhier F; Messaoudi K; Lemaire L; Benoit JP; Lagarce F
    Int J Pharm; 2015 Mar; 481(1-2):154-61. PubMed ID: 25644286
    [TBL] [Abstract][Full Text] [Related]  

  • 33. miR‑146b‑5p suppresses glioblastoma cell resistance to temozolomide through targeting TRAF6.
    Qian Z; Zhou S; Zhou Z; Yang X; Que S; Lan J; Qiu Y; Lin Y
    Oncol Rep; 2017 Nov; 38(5):2941-2950. PubMed ID: 29048680
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma.
    Verreault M; Wehbe M; Strutt D; Masin D; Anantha M; Walker D; Chu F; Backstrom I; Kalra J; Waterhouse D; Yapp DT; Bally MB
    J Control Release; 2015 Dec; 220(Pt A):348-357. PubMed ID: 26528901
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metformin treatment reduces temozolomide resistance of glioblastoma cells.
    Yang SH; Li S; Lu G; Xue H; Kim DH; Zhu JJ; Liu Y
    Oncotarget; 2016 Nov; 7(48):78787-78803. PubMed ID: 27791206
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chloroquine enhances temozolomide cytotoxicity in malignant gliomas by blocking autophagy.
    Golden EB; Cho HY; Jahanian A; Hofman FM; Louie SG; Schönthal AH; Chen TC
    Neurosurg Focus; 2014 Dec; 37(6):E12. PubMed ID: 25434381
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Temozolomide-loaded photopolymerizable PEG-DMA-based hydrogel for the treatment of glioblastoma.
    Fourniols T; Randolph LD; Staub A; Vanvarenberg K; Leprince JG; Préat V; des Rieux A; Danhier F
    J Control Release; 2015 Jul; 210():95-104. PubMed ID: 25982679
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in Glioblastoma.
    Pokorny JL; Calligaris D; Gupta SK; Iyekegbe DO; Mueller D; Bakken KK; Carlson BL; Schroeder MA; Evans DL; Lou Z; Decker PA; Eckel-Passow JE; Pucci V; Ma B; Shumway SD; Elmquist WF; Agar NY; Sarkaria JN
    Clin Cancer Res; 2015 Apr; 21(8):1916-24. PubMed ID: 25609063
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The PI3K inhibitor GDC-0941 enhances radiosensitization and reduces chemoresistance to temozolomide in GBM cell lines.
    Shi F; Guo H; Zhang R; Liu H; Wu L; Wu Q; Liu J; Liu T; Zhang Q
    Neuroscience; 2017 Mar; 346():298-308. PubMed ID: 28147244
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intranasal delivery of targeted polyfunctional gold-iron oxide nanoparticles loaded with therapeutic microRNAs for combined theranostic multimodality imaging and presensitization of glioblastoma to temozolomide.
    Sukumar UK; Bose RJC; Malhotra M; Babikir HA; Afjei R; Robinson E; Zeng Y; Chang E; Habte F; Sinclair R; Gambhir SS; Massoud TF; Paulmurugan R
    Biomaterials; 2019 Oct; 218():119342. PubMed ID: 31326657
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.